Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|March 21, 2012
Phase II dose-ranging trial of the early bactericidal activity of PA-824Andreas H Diacon, Rodney Dawson, Jeannine du Bois, et al.
Diabetes, Obesity & Metabolism|March 1, 2017
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsBruce Neal, Vlado Perkovic, Kenneth W Mahaffey, et al.
Obesity (Silver Spring, Md.)|April 12, 2007
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight lossNgozi Erondu, Thomas Wadden, Ira Gantz, et al.
Diabetes, Obesity & Metabolism|January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trialBruce Neal, Vlado Perkovic, David R Matthews, et al.
PLOS Global Public Health|June 20, 2024
Facilitators and barriers to community-led monitoring of health programs: Qualitative evidence from the global implementation landscapeAlana R Sharp, Ngqabutho Mpofu, Elise Lankiewicz, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosisAndreas H Diacon, Rodney Dawson, Florian Von Groote-Bidlingmaier, et al.
The Journal of Clinical Endocrinology and Metabolism|March 8, 2007
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adultsIra Gantz, Ngozi Erondu, Madhuja Mallick, et al.
Obesity (Silver Spring, Md.)|August 23, 2007
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineNgozi Erondu, Carol Addy, Kaifeng Lu, et al.
Plos One|March 2, 2023
Creation of an ustekinumab external control arm for Crohn's disease using electronic health records data: A pilot studyVivek A Rudrapatna, Yao-Wen Cheng, Colin Feuille, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
Pageof 4